Repaglinide 1 MG Oral Tablet — RxCUI 200256
RxNorm drug concept · Semantic clinical drug
RxCUI 200256
Semantic clinical drug · SCD
● Current RxNorm concept 17 FDA products
29 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI200256
Official nameRepaglinide 1 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped17
Package NDCs mapped29
Reported Medicaid activity (SDUD)35,750 prescriptions · 25 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Repaglinide: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Repaglinide helps your pancreas release insulin when you eat a meal, which brings your blood sugar down. If you have type 2 diabetes, your body either doesn't make enough insulin o...
- What exactly does repaglinide do, and why do I need it?
- Repaglinide works by triggering insulin release, and you want that insulin to be available when food hits your bloodstream. Take it within 30 minutes before each meal. If you forge...
- Why do I have to take it right before eating? What happens if I forget?
🕸️ Concept Web — How Repaglinide 1 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Repaglinide 1 MG Oral Tablet
RxCUI 200256 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Repaglinide
73044IN
-
Repaglinide
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Repaglinide Oral Tablet
373759SCDF -
Repaglinide Oral Product
1157407SCDG -
Repaglinide Pill
1157408SCDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Repaglinide Oral Tablet
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Repaglinide 1 MG
316630SCDC
-
Repaglinide 1 MG
Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Repaglinide 1 MG
SCDC · 316630 -
Repaglinide Oral Tablet
SCDF · 373759 -
Repaglinide Oral Product
SCDG · 1157407 -
Repaglinide Pill
SCDG · 1157408
📦 FDA Products & Package NDCs
17 products · 29 package NDCs
29 package NDCs map to RxCUI 200256 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 33342-0248-11 | 100 TABLET in 1 BOTTLE (33342-248-11) | Repaglinide | Macleods Pharmaceuticals Limited | 2023-03-22 |
| 33342-0248-44 | 1000 TABLET in 1 BOTTLE (33342-248-44) | Repaglinide | Macleods Pharmaceuticals Limited | 2023-03-22 |
| 33342-0249-11 | 100 TABLET in 1 BOTTLE (33342-249-11) | Repaglinide | Macleods Pharmaceuticals Limited | 2023-03-22 |
| 33342-0249-44 | 1000 TABLET in 1 BOTTLE (33342-249-44) | Repaglinide | Macleods Pharmaceuticals Limited | 2023-03-22 |
| 33342-0250-11 | 100 TABLET in 1 BOTTLE (33342-250-11) | Repaglinide | Macleods Pharmaceuticals Limited | 2023-03-22 |
| 33342-0250-44 | 1000 TABLET in 1 BOTTLE (33342-250-44) | Repaglinide | Macleods Pharmaceuticals Limited | 2023-03-22 |
| 57237-0157-01 | 100 TABLET in 1 BOTTLE (57237-157-01) | Repaglinide | Rising Pharma Holdings, Inc. | 2014-01-22 |
| 57237-0157-05 | 500 TABLET in 1 BOTTLE (57237-157-05) | Repaglinide | Rising Pharma Holdings, Inc. | 2014-01-22 |
| 57237-0158-01 | 100 TABLET in 1 BOTTLE (57237-158-01) | Repaglinide | Rising Pharma Holdings, Inc. | 2014-01-22 |
| 57237-0158-05 | 500 TABLET in 1 BOTTLE (57237-158-05) | Repaglinide | Rising Pharma Holdings, Inc. | 2014-01-22 |
| 57237-0159-01 | 100 TABLET in 1 BOTTLE (57237-159-01) | Repaglinide | Rising Pharma Holdings, Inc. | 2014-01-22 |
| 57237-0159-05 | 500 TABLET in 1 BOTTLE (57237-159-05) | Repaglinide | Rising Pharma Holdings, Inc. | 2014-01-22 |
| 60687-0560-21 | 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-560-21) / 1 TABL... | Repaglinide | American Health Packaging | 2020-09-17 |
| 62135-0946-90 | 90 TABLET in 1 BOTTLE (62135-946-90) | Repaglinide | Chartwell RX, LLC | 2025-04-24 |
| 62135-0947-90 | 90 TABLET in 1 BOTTLE (62135-947-90) | Repaglinide | Chartwell RX, LLC | 2025-04-24 |
| 62135-0948-90 | 90 TABLET in 1 BOTTLE (62135-948-90) | Repaglinide | Chartwell RX, LLC | 2025-04-24 |
| 65862-0670-01 | 100 TABLET in 1 BOTTLE (65862-670-01) | Repaglinide | Aurobindo Pharma Limited | 2014-01-22 |
| 65862-0670-05 | 500 TABLET in 1 BOTTLE (65862-670-05) | Repaglinide | Aurobindo Pharma Limited | 2014-01-22 |
| 65862-0670-99 | 1000 TABLET in 1 BOTTLE (65862-670-99) | Repaglinide | Aurobindo Pharma Limited | 2014-01-22 |
| 65862-0671-01 | 100 TABLET in 1 BOTTLE (65862-671-01) | Repaglinide | Aurobindo Pharma Limited | 2014-01-22 |
| 65862-0671-05 | 500 TABLET in 1 BOTTLE (65862-671-05) | Repaglinide | Aurobindo Pharma Limited | 2014-01-22 |
| 65862-0671-99 | 1000 TABLET in 1 BOTTLE (65862-671-99) | Repaglinide | Aurobindo Pharma Limited | 2014-01-22 |
| 65862-0672-01 | 100 TABLET in 1 BOTTLE (65862-672-01) | Repaglinide | Aurobindo Pharma Limited | 2014-01-22 |
| 65862-0672-05 | 500 TABLET in 1 BOTTLE (65862-672-05) | Repaglinide | Aurobindo Pharma Limited | 2014-01-22 |
| 65862-0672-99 | 1000 TABLET in 1 BOTTLE (65862-672-99) | Repaglinide | Aurobindo Pharma Limited | 2014-01-22 |
| 72162-2558-01 | 100 TABLET in 1 BOTTLE (72162-2558-1) | Repaglinide | Bryant Ranch Prepack | 2025-11-04 |
| 72603-0810-01 | 100 TABLET in 1 BOTTLE (72603-810-01) | Repaglinide | NorthStar RxLLC | 2025-04-08 |
| 72603-0811-01 | 100 TABLET in 1 BOTTLE (72603-811-01) | Repaglinide | NorthStar RxLLC | 2025-04-08 |
| 72603-0812-01 | 100 TABLET in 1 BOTTLE (72603-812-01) | Repaglinide | NorthStar RxLLC | 2025-04-08 |
Observed labelers:
Aurobindo Pharma Limited (9) ·
Macleods Pharmaceuticals Limited (6) ·
Rising Pharma Holdings, Inc. (6) ·
Chartwell RX, LLC (3) ·
NorthStar RxLLC (3) ·
American Health Packaging (1)
· +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.